- Home
- PAM vs NAMS Comparison
PAM vs NAMS Comparison
Compare PAM & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAM | NAMS |
|---|---|---|
| Founded | 1945 | 2019 |
| Country | Argentina | Netherlands |
| Employees | 1847 | 100 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PAM | NAMS |
|---|---|---|
| Price | $86.26 | $29.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $94.50 | $46.75 |
| AVG Volume (30 Days) | 135.1K | ★ 961.2K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $204,770.38 | $17.96 |
| Revenue Next Year | $16.65 | $540.65 |
| P/E Ratio | $13.79 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.95 | $21.14 |
| 52 Week High | $94.50 | $42.21 |
Technical Indicators
Market Signals| Indicator | PAM | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 55.58 | 41.00 |
| Support Level | $79.02 | $29.23 |
| Resistance Level | $89.52 | $37.29 |
| Average True Range (ATR) | 2.46 | 1.88 |
| MACD | 0.64 | -0.42 |
| Stochastic Oscillator | 59.01 | 8.00 |
Price Performance
Historical ComparisonAbout PAM Pampa Energia S.A.
Pampa Energia SA and its subsidiaries are engaged in the Energy business, mainly in oil and gas production and power generation. The firm's operating business segments are Oil and Gas, Generation, Petrochemicals, Holding, Transportation, and Others. The company derives the maximum revenue from the oil and gas segment.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.